Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of fixed-dose relatlimab + nivolumab in Chinese patients with advanced solid tumors
CTR20212216Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of relatlimab and nivolumab in Nonhematologic neoplasms, sponsored by Bristol Myers Squibb. Primary endpoints: Safety and Relatlimab pharmacokinetics. Started Dec 2021; status: active.
02
Drugs
relatlimabnivolumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20212216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212216.